The managed care cohort received a collective lift after UnitedHealth raised its guidance, yet the most striking valuation gap today belongs to Cigna (CI). Cigna trades at 12.3x trailing earnings and carries a 53.9% Fair Value upside, creating a valuation profile that appears considerably cheaper than peers. At the same time, UnitedHealth (UNH) functions as the dependable quality anchor for the sector, and HCA Healthcare (HCA) posts the highest net margins in the group at 8.8%.
The competitive set
Five firms dominate the managed care landscape covered here. The snapshot below preserves the key market metrics used to compare them:
| Company | Price | Mkt Cap | P/E (LTM) | P/E (Fwd) | FCF Yield | FV Upside | Fin. Health |
|---|---|---|---|---|---|---|---|
| UnitedHealth (UNH) | $417.91 | $379.21B | 26.9x | 21.3x | 6.2% | +21.1% | Good |
| Cigna (CI) | $291.61 | $77.14B | 12.3x | 9.6x | 9.9% | +53.9% | Great |
| Elevance Health (ELV) | $378.37 | $82.06B | 16.5x | 13.9x | 7.7% | +12.3% | Good |
| HCA Healthcare (HCA) | $389.81 | $86.85B | 12.7x | 12.9x | 6.9% | +22.8% | Great |
| CVS Health (CVS) | $106.92 | $136.37B | 46.5x | 14.4x | 5.4% | +27.6% | Good |
Value champion - Cigna (CI)
Cigna emerges as the valuation outlier. The company carries a forward P/E of 9.6x and a Fair Value upside of 53.9%. Over the past five years its revenue expanded from $174B to $274.9B, a total increase of 58%. Free cash flow yield registers at 9.9%, the highest in the peer group, and the company’s financial health is rated "Great." Management has scaled an AI-powered care management program targeting $200M in savings over three years. The firm also declared a quarterly dividend of $1.56 per share, representing a 2.2% yield.
Bear case: Cigna’s thin net margins of 2.3% and a debt-to-equity ratio of 73% reduce the cushion if medical cost ratios move against the company.
Quality anchor - UnitedHealth (UNH)
UnitedHealth is the blue-chip name in the cohort. With a market capitalization of $379B and revenues of $447.6B, it operates at a much larger scale than its peers. Management raised 2026 adjusted EPS guidance to a range of $19.50 to $20.00, a move that helped lift sector sentiment. The current price of $417.91 compares with a Fair Value of $506, implying 21.1% upside and a dividend yield assumption of 2.2%.
Bear case: UnitedHealth’s premium valuation - 26.9x LTM P/E - means the stock is sensitive to any earnings disappointments.
Margin leader - HCA Healthcare (HCA)
HCA’s operating model as a hospital operator drives superior profitability within the set. Net income margin of 8.8% is substantially above the peer median - roughly three times Cigna’s margin and four times Elevance’s - underscoring HCA’s pricing leverage. The Fair Value of $478.51 suggests 22.8% upside relative to the $389.81 share price. Research coverage includes a Barclays reduction in its target to $402 from $427; that lowered target still sits above the current market price.
Bear case: HCA flagged weaker-than-expected elective surgical volumes in Q2, which has implications for the broader medical device sector and hospital utilization trends.
Additional observations
- Best pure value: Cigna - lowest P/E, highest FCF yield, and the largest Fair Value gap.
- Best quality/safety: UnitedHealth - scale, a guidance raise, and consistent execution underpin this view.
- Best margin profile: HCA Healthcare - 8.8% net margin versus a sector average near 3%.
- Watch for recovery: Elevance experienced a sell-off of about 8.5% on Jul 16 despite a Guggenheim target of $455, a move some consider overblown.
- Avoid for now: CVS’s 46.5x trailing P/E appears rich; potential fallout from an FTC settlement that could affect its PBM model adds uncertainty.
Context and implications
The guidance lift from UnitedHealth provided a positive tone across the sector, but investor focus should differ by objective. Value-seeking investors may prefer the risk/reward profile of Cigna given the sizable Fair Value gap and elevated free cash flow yield. Income or safety-focused investors may continue to favor UnitedHealth for scale and stability, while those seeking margin resilience could look to HCA. Regulatory developments affecting PBMs and elective procedure volumes remain key near-term drivers to monitor for CVS and HCA, respectively.